Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only

In a prostate-cancer screening trial involving men with lesions shown on MRI, targeted biopsy alone detected half as many clinically insignificant tumors as targeted and systematic biopsy, with few significant tumors missed.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 23; pp. 2126 - 2137
Main Authors Hugosson, Jonas, Månsson, Marianne, Wallström, Jonas, Axcrona, Ulrika, Carlsson, Sigrid V., Egevad, Lars, Geterud, Kjell, Khatami, Ali, Kohestani, Kimia, Pihl, Carl-Gustaf, Socratous, Andreas, Stranne, Johan, Godtman, Rebecka Arnsrud, Hellström, Mikael
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 08.12.2022
Subjects
Biopsy
Cancer screening
Clinical significance
diagnostic imaging
Early Detection of Cancer
Genitourinary Cancer
Hematology
Humans
Laboratories
Magnetic Resonance Imaging
Male
Medical screening
Medicin och hälsovetenskap
Mortality
Oncology
Patients
Prostate cancer
Prostate Disease
Prostate Disease General
Prostate-Specific Antigen
Prostatic Neoplasms
Prostatic Neoplasms - diagnostic imaging
Radiology
Radiology General
Social Group
Tumors
Ultrasonic imaging
Urologi och njurmedicin
Urology
Urology and Nephrology
Online AccessGet full text

Cover

More Information
Summary:In a prostate-cancer screening trial involving men with lesions shown on MRI, targeted biopsy alone detected half as many clinically insignificant tumors as targeted and systematic biopsy, with few significant tumors missed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
A list of the GÖTEBORG-2 trial investigators is provided in the Supplementary Appendix, available at NEJM.org.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2209454